Publications by authors named "L Boloko"
Article Synopsis
- Tuberculosis (TB) is a major global health issue, and the standard treatment regimen, particularly the dose of rifampicin, has not significantly changed in fifty years, leading researchers to investigate higher doses.* -
- A systematic review analyzed data from 19 studies involving 6,332 patients to assess the efficacy and safety of rifampicin doses over 8-35 mg/kg, but found no improved efficacy with higher doses and potential liver injury risks at doses above 20 mg/kg.* -
- The findings indicate that while higher doses of rifampicin might not enhance treatment effectiveness for TB, the risk of liver damage is a concern, suggesting a need for larger clinical trials to better understand the implications.*
Article Synopsis
- HIV-associated tuberculosis (TB) leads to high mortality rates, especially in severely ill hospitalized patients, prompting this study to evaluate enhanced treatments.
- The study assesses the effectiveness and safety of high-dose rifampicin combined with levofloxacin and the use of corticosteroids for reducing early mortality in HIV-positive patients with disseminated TB.
- A phase III trial design tests these interventions against standard treatments, focusing on all-cause mortality and safety metrics over various timelines.
Background: The emergence of genetic variants of SARS-CoV-2 was associated with changing epidemiological characteristics throughout coronavirus disease 2019 (COVID-19) pandemic in population-based studies. Individual-level data on the clinical characteristics of infection with different SARS-CoV-2 variants in African countries is less well documented.
Objectives: To describe the evolving clinical differences observed with the various SARS-CoV-2 variants of concern and compare the Omicron-driven wave in infections to the previous Delta-driven wave.
Objectives: We aimed to compare the clinical severity of Omicron BA.4/BA.5 infection with BA.
View Article and Find Full Text PDF